US04216R1023
© PR Newswire
13.01.2026
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
News Preview
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3studyFirst bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
News Preview
LOS ANGELES, Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
News Preview
LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
10.11.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
News Preview
LOS ANGELES, Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
22.10.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
News Preview
LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
© PR Newswire
14.10.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
News Preview
LOS ANGELES, Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
News Preview
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02
LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specifi...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today annou...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
News Preview
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02
LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the devel...
Themefolio
Profiler
Peergroup
© PR Newswire
19.05.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
News Preview
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met
AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy
No treatment-related serious adverse events were observed with repetitive intravenous dosing
LOS ANGELES, May 19, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
News Preview
LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
News Preview
Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia
Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial
LOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechno...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.03.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
News Preview
LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today anno...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
News Preview
Proceeds to be used to continue to advance development of Armata's phage product candidates
LOS ANGELES, March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for t...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
News Preview
LOS ANGELES, March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today annou...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
News Preview
Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the developme...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
News Preview
LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Offic...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
News Preview
LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
News Preview
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025
LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Ch...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
News Preview
LOS ANGELES, Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., M...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
News Preview
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sci...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
News Preview
LOS ANGELES, Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended...
Themefolio
Profiler
Peergroup
© PR Newswire
30.07.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
News Preview
Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia
LOS ANGELES, July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therap...
Themefolio
Profiler
Peergroup
© PR Newswire
11.07.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
News Preview
Tailwind is evaluating inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB), its second patient population, following successful evaluation in patients with cystic fibrosis (SWARM-P.a.) in 2023
Phase 2 Topline data anticipated in 2H 2024 followed by potential initiation of a pivotal bronchiectasis trial in 2025
LOS ANGELES, July 11, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
News Preview
LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Com...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
News Preview
LOS ANGELES, May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended Ma...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
News Preview
LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2024
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
News Preview
LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliv...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
